See more : Suntory Beverage & Food Limited (STBFY) Income Statement Analysis – Financial Results
Complete financial analysis of Todos Medical Ltd. (TOMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Todos Medical Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Anjani Portland Cement Limited (APCL.NS) Income Statement Analysis – Financial Results
- GigCapital4, Inc. (GIGGU) Income Statement Analysis – Financial Results
- Tronox Pigmentos do Brasil S.A. (CRPG5.SA) Income Statement Analysis – Financial Results
- Eastern Silk Industries Limited (EASTSILK.BO) Income Statement Analysis – Financial Results
- Morgan Stanley (MS-PE) Income Statement Analysis – Financial Results
Todos Medical Ltd. (TOMDF)
About Todos Medical Ltd.
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.70M | 12.23M | 5.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.39M | 7.85M | 3.82M | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.31M | 4.38M | 1.39M | -29.64K | -25.65K | -24.08K | -20.70K | -11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 56.01% | 35.84% | 26.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 620.00K | 824.00K | 9.86M | 755.70K | 459.18K | 720.53K | 317.91K | 374.02K | 336.47K | 377.31K | 312.17 |
| General & Administrative | 0.00 | 9.36M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Selling & Marketing | 0.00 | 3.48M | -3.06M | -667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.85M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Other Expenses | 0.00 | 0.00 | -53.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.06M | 13.67M | 15.65M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Cost & Expenses | 17.44M | 21.52M | 19.47M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Interest Income | 0.00 | 28.61K | 13.37K | 959.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Interest Expense | 14.85M | 28.61M | 3.83M | 958.74K | 75.43K | 12.44K | 78.78K | 0.00 | 0.00 | ||
| Depreciation & Amortization | 750.00K | 763.00K | 96.00K | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 434.00 | 275.00 | 0.28 |
| EBITDA | -9.39M | -9.72M | -14.17M | -7.78M | -1.35M | -1.31M | -708.19K | -819.08K | -400.41K | -339.26K | -244.22 |
| EBITDA Ratio | -122.08% | -59.33% | -465.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.75M | -9.29M | -14.26M | -3.52M | -1.38M | -1.34M | -728.89K | -830.98K | -400.85K | -339.53K | -244.49 |
| Operating Income Ratio | -126.68% | -75.93% | -273.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.23M | -34.03M | -15.51M | -8.30M | 921.34K | -1.34M | 75.43K | 12.44K | 78.78K | -42.29K | -11.63 |
| Income Before Tax | -24.98M | -43.31M | -29.77M | -11.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -381.82K | -256.12 |
| Income Before Tax Ratio | -324.64% | -354.16% | -571.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | 31.61M | 2.63M | -2.01M | 871.34K | -2.68M | 0.00 | 0.00 | 0.00 | -38.18K | -25.37 |
| Net Income | -24.99M | -74.92M | -32.40M | -9.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -343.64K | -230.75 |
| Net Income Ratio | -324.81% | -612.60% | -622.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
| Weighted Avg Shares Out (Dil) | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
Todos Medical announces 2nd site for Tollovir Phase 2 clinical trial for the treatment of hospitalized coronavirus patients
Todos Medical notes publication of article in 'Nature Neuroscience' by researchers in Germany which has positive implications for its Tollovir drug
Todos Medical says journal article highlights utility of combining cPass and PCR testing to reduce COVID-19 transmission
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Todos Medical gears up to expand its coronavirus testing services and clinical study
Todos Medical unveils positive clinical validation data for its 3CL protease biomarker assay TolloTest in a clinical study of COVID-19 patients
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
UPDATE - Todos Medical Announces October Conference Calendar
Todos Medical updates on its COVID-19 antiviral 3CL protease inhibitor Tollovir clinical development program in Israel
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Source: https://incomestatements.info
Category: Stock Reports